NEJM:重磅!雷地西韦治疗重症Covid-19患者临床结果公布

2020-04-11 MedSci原创 MedSci原创

最近,研究人员为因感染SARS-CoV-2引起的Covid-19的住院患者提供了remdesivir。

Remdesivir是一种能抑制病毒RNA聚合酶的核苷酸类似物原药,在体外显示出对SARS-CoV-2的活性。

最近,研究人员为因感染SARS-CoV-2引起的Covid-19的住院患者提供了remdesivir。治疗的患者为呼吸环境空气时血氧饱和度为94%或更低的SARS-CoV-2感染确诊患者,或正在接受氧气支持的患者。

患者接受为期10天的remdesivir治疗,包括第1天静脉注射200mg,其余9天治疗期间每天100mg。

本报告是基于2020年1月25日到2020年3月7日期间接受remdesivir治疗的患者的数据,并有至少1天后的临床数据。

结果显示,在61名至少接受过一次雷地西韦治疗的患者中,有8名患者的数据无法分析(其中7名患者没有治疗后数据,1名患者出现了剂量错误)。

在53名数据被分析的患者中,22名患者在美国,22名在欧洲或加拿大,9名在日本。在基线时,30名患者(57%)接受机械通气,4名(8%)接受体外膜吸氧。在18天的中位随访期间,36名患者(68%)的供氧量级有所改善,其中30名接受机械通气的患者(57%)中,有17名患者(57%)接受了插管。共有25名患者(47%)出院,7名患者(13%)死亡;接受有创通气的患者死亡率为18%(34人中有6人),未接受有创通气的患者死亡率为5%(19人中有1人)。

因此,在这组因重症Covid-19住院的患者中,53名患者中的36名(68%)接受了同情用药remdesivir治疗,观察到临床改善。疗效的测量需要持续的随机、安慰剂对照的remdesivir治疗试验。

 

原始出处:

Jonathan Grein et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. NEJM 2020; 

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2004409, encodeId=63b6200440912, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Jun 01 00:10:53 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898844, encodeId=81a51898844e4, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Mon Jun 15 08:10:53 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297425, encodeId=c78e129e425f5, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Apr 13 00:10:53 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549571, encodeId=f15815495e191, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Apr 13 00:10:53 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035220, encodeId=53a31035220d3, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Apr 11 12:10:53 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2004409, encodeId=63b6200440912, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Jun 01 00:10:53 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898844, encodeId=81a51898844e4, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Mon Jun 15 08:10:53 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297425, encodeId=c78e129e425f5, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Apr 13 00:10:53 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549571, encodeId=f15815495e191, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Apr 13 00:10:53 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035220, encodeId=53a31035220d3, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Apr 11 12:10:53 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2004409, encodeId=63b6200440912, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Jun 01 00:10:53 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898844, encodeId=81a51898844e4, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Mon Jun 15 08:10:53 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297425, encodeId=c78e129e425f5, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Apr 13 00:10:53 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549571, encodeId=f15815495e191, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Apr 13 00:10:53 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035220, encodeId=53a31035220d3, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Apr 11 12:10:53 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2004409, encodeId=63b6200440912, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Jun 01 00:10:53 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898844, encodeId=81a51898844e4, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Mon Jun 15 08:10:53 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297425, encodeId=c78e129e425f5, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Apr 13 00:10:53 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549571, encodeId=f15815495e191, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Apr 13 00:10:53 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035220, encodeId=53a31035220d3, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Apr 11 12:10:53 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
    2020-04-13 xxxx1054
  5. [GetPortalCommentsPageByObjectIdResponse(id=2004409, encodeId=63b6200440912, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78621, encryptionId=54ebe8621cf, topicName=结果公布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Jun 01 00:10:53 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898844, encodeId=81a51898844e4, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Mon Jun 15 08:10:53 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297425, encodeId=c78e129e425f5, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Apr 13 00:10:53 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549571, encodeId=f15815495e191, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Apr 13 00:10:53 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035220, encodeId=53a31035220d3, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sat Apr 11 12:10:53 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
    2020-04-11 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

OBESITY:新冠疫情或导致儿童肥胖大流行

尽管减轻其直接影响是一个优先事项,但研究人员提醒人们注意这一流行病对儿童健康的长期影响。

盘点:2020年度Radiology科研进展汇总(三)

2020年度Radiology科研进展汇总

空气污染恐增新冠肺炎致死率!

全球每年有700万人因空气污染而死,空气污染与新冠肺炎又有什么关系?

新型冠状病毒治疗药物和疫苗研发的新近进展

冠状病毒治疗最终只有靠药物和疫苗。据中国工程院院士王军志介绍,国内新冠疫苗研发从五大技术方向推进,包括灭活疫苗、基因工程重组亚单位疫苗、腺病毒载体疫苗、减毒流感病毒载体疫苗和核酸疫苗。其中,第一批确定

NATURE:COVID-2019年住院患者的病毒学评估报告 

最近,研究人员对9例病例进行了详细的病毒学分析,提供了上呼吸道组织中病毒复制活跃的证据。

欧洲首组新冠临床与病毒学分析,其真正含义是什么?

这些发现将有助于更好地了解新冠病毒特征。